ArticleCell and tissue research2026
FGF19 promotes cartilage destruction in the progress of temporomandibular joint osteoarthritis.
Article in Cell and tissue research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporomandibular joint osteoarthritis (TMJOA) is a degenerative joint disease characterized by the progressive deterioration of the condylar cartilage, compensatory remodeling of subchondral bone, and persistent synovial inflammation. The onset of TMJOA is accompanied by the activation of cytokines, which exacerbate the imbalance in joint homeostasis and accelerate the destruction and even irreversible degradation of joint structures. FGF19, as an important multifunctional fibroblast growth factor, has been reported to be substantially up-regulated in the cavity of osteoarthritis joint. However, its role in TMJOA progression remains unclear. In this study, we investigated its role in the condyle cartilage in TMJOA. We first established a mouse TMJOA model by unilateral anterior crossbite (UAC) and achieved overexpression of FGF19 by direct injection of adeno-associated virus carrying the Fgf19 gene. We found that FGF19 exacerbated the progressive deterioration of cartilage-subchondral bone unit in the progression of TMJOA. FGF19 accelerated the phenotypic transformation from mature cartilage to hypertrophic cartilage by reducing the expression of collagen type II (COL2A1) and aggrecan, enhancing the expression of collagen type X (COL10A1), matrix metallopeptidase 13 (MMP13), and a disintegrin and metalloproteinase with thrombospondin 5 (ADAMTS5), and exhibiting a fibrocartilage-associated change in the cartilage layer by increasing the expression of collagen type I alpha 1 and 2 (COL1A1 and COL1A2). Furthermore, FGF19 induces calcification progression of cartilage hypertrophic layer by up-regulating the expression of dentin matrix acidic phosphoprotein 1 (DMP1) via transcription factor osterix (OSX). These data provide evidence of the importance of FGF19 in the progression of TMJOA and show potential cues for interventions of cartilage disease.
Indexed as
Identifiers
42247043What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.